Thai N. Truong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thai N. Truong has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Annabelle Pan
Johns Hopkins University School of Medicine, Baltimore MD 21205, USA
1 shared publication - Doan Y. Dao
Center of Excellence for Liver Disease in Viet Nam, Johns Hopkins School of Medicine, Baltimore, MD, USA
1 shared publication - Ying-Hsiu Su
The Baruch S. Blumberg Institute, Translational Medical Science
1 shared publication
Latest Publications
- Open Access
- 11 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (4) , 676
Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings
Hepatocellular carcinoma (HCC) is among the world’s third most lethal cancers. In resource-limited settings (RLS), up to 70% of HCCs are diagnosed with limited curative treatments at an advanced symptomatic stage. Even when HCC is detected early and resection surgery is offered, the post-operative recurrence rate after resection exceeds 70% in five years, of which about 50% occur within two years of surgery. There are no specific biomarkers addressing the surveillance of HCC recurrence due to the limited sensitivity of the available methods. The primary goal in the early diagnosis and management of HCC is to cure disease and improve survival, respectively. Circulating biomarkers can be used as screening, diagnostic, prognostic, and predictive biomarkers to achieve the primary goal of HCC. In this review, we highlighted key circulating blood- or urine-based HCC biomarkers and considered their potential applications in resource-limited settings, where the unmet medical needs of HCC are disproportionately highly significant.
- 11 February 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (4) , 676
Open AccessCirculating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings
Hepatocellular carcinoma (HCC) is among the world’s third most lethal cancers. In resource-limited settings (RLS), up to 70% of HCCs are diagnosed with limited curative treatments at an advanced symptomatic stage. Even when HCC is detected early and resection surgery is offered, the post-operative recurrence rate after resection exceeds 70% in five years, of which about 50% occur within two years of surgery. There are no specific biomarkers addressing the surveillance of HCC recurrence due to the limited sensitivity of the available methods. The primary goal in the early diagnosis and management of HCC is to cure disease and improve survival, respectively. Circulating biomarkers can be used as screening, diagnostic, prognostic, and predictive biomarkers to achieve the primary goal of HCC. In this review, we highlighted key circulating blood- or urine-based HCC biomarkers and considered their potential applications in resource-limited settings, where the unmet medical needs of HCC are disproportionately highly significant.